Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in San Carlos, CA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
61
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Allakos Inc market cap is $29.74M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Allakos Inc 52 week high is $1.56 as of November 18, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Allakos Inc 52 week low is $0.2157 as of November 18, 2026.
Allakos Inc stock price today is $0.3291.
Allakos Inc stock price yesterday was $0.3293.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Allakos Inc's P/E ratio is -0.41.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Allakos Inc P/B ratio is 0.5363.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Allakos Inc 50-day moving average is $0.3035.